nodes	percent_of_prediction	percent_of_DWPC	metapath
Galantamine—CYP3A4—bone cancer	0.765	1	CbGaD
Galantamine—Dihydrocodeine—CYP3A4—bone cancer	0.00218	0.222	CrCbGaD
Galantamine—Ethylmorphine—CYP3A4—bone cancer	0.00182	0.186	CrCbGaD
Galantamine—Hydrocodone—CYP3A4—bone cancer	0.00167	0.17	CrCbGaD
Galantamine—Oxycodone—CYP3A4—bone cancer	0.00152	0.155	CrCbGaD
Galantamine—Codeine—CYP3A4—bone cancer	0.00145	0.148	CrCbGaD
Galantamine—CHRNB2—SIDS Susceptibility Pathways—FEV—bone cancer	0.00139	0.058	CbGpPWpGaD
Galantamine—Morphine—CYP3A4—bone cancer	0.00118	0.12	CrCbGaD
Galantamine—CHRNB4—SIDS Susceptibility Pathways—FEV—bone cancer	0.0011	0.0457	CbGpPWpGaD
Galantamine—CHRNA7—SIDS Susceptibility Pathways—FEV—bone cancer	0.000952	0.0396	CbGpPWpGaD
Galantamine—CHRNA4—SIDS Susceptibility Pathways—FEV—bone cancer	0.000776	0.0323	CbGpPWpGaD
Galantamine—CHRNB2—Circadian rythm related genes—TNFRSF11A—bone cancer	0.000733	0.0305	CbGpPWpGaD
Galantamine—BCHE—Irinotecan Pathway—CYP3A4—bone cancer	0.000672	0.028	CbGpPWpGaD
Galantamine—Hypokalaemia—Doxorubicin—bone cancer	0.000544	0.0027	CcSEcCtD
Galantamine—Decreased appetite—Cisplatin—bone cancer	0.000537	0.00267	CcSEcCtD
Galantamine—Bronchitis—Epirubicin—bone cancer	0.000537	0.00266	CcSEcCtD
Galantamine—Pneumonia—Methotrexate—bone cancer	0.000535	0.00266	CcSEcCtD
Galantamine—Gastrointestinal disorder—Cisplatin—bone cancer	0.000534	0.00265	CcSEcCtD
Galantamine—Depression—Methotrexate—bone cancer	0.00053	0.00263	CcSEcCtD
Galantamine—Gastritis—Doxorubicin—bone cancer	0.000529	0.00263	CcSEcCtD
Galantamine—Muscular weakness—Doxorubicin—bone cancer	0.000527	0.00262	CcSEcCtD
Galantamine—Renal failure—Methotrexate—bone cancer	0.000523	0.0026	CcSEcCtD
Galantamine—Upper respiratory tract infection—Epirubicin—bone cancer	0.000519	0.00258	CcSEcCtD
Galantamine—Dysphagia—Doxorubicin—bone cancer	0.000517	0.00256	CcSEcCtD
Galantamine—Pollakiuria—Epirubicin—bone cancer	0.000516	0.00256	CcSEcCtD
Galantamine—Feeling abnormal—Cisplatin—bone cancer	0.000509	0.00253	CcSEcCtD
Galantamine—Haematuria—Methotrexate—bone cancer	0.000507	0.00252	CcSEcCtD
Galantamine—Weight decreased—Epirubicin—bone cancer	0.000505	0.00251	CcSEcCtD
Galantamine—Hyperglycaemia—Epirubicin—bone cancer	0.000504	0.0025	CcSEcCtD
Galantamine—Hepatobiliary disease—Methotrexate—bone cancer	0.000503	0.0025	CcSEcCtD
Galantamine—Epistaxis—Methotrexate—bone cancer	0.000502	0.00249	CcSEcCtD
Galantamine—Pneumonia—Epirubicin—bone cancer	0.000501	0.00248	CcSEcCtD
Galantamine—Bronchitis—Doxorubicin—bone cancer	0.000497	0.00247	CcSEcCtD
Galantamine—Renal failure—Epirubicin—bone cancer	0.000489	0.00243	CcSEcCtD
Galantamine—Body temperature increased—Cisplatin—bone cancer	0.000489	0.00243	CcSEcCtD
Galantamine—Neuropathy peripheral—Epirubicin—bone cancer	0.000488	0.00242	CcSEcCtD
Galantamine—Urinary tract infection—Epirubicin—bone cancer	0.000484	0.0024	CcSEcCtD
Galantamine—CYP2D6—Codeine and Morphine Metabolism—CYP3A4—bone cancer	0.000483	0.0201	CbGpPWpGaD
Galantamine—CYP2D6—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000481	0.02	CbGpPWpGaD
Galantamine—Upper respiratory tract infection—Doxorubicin—bone cancer	0.00048	0.00238	CcSEcCtD
Galantamine—Haemoglobin—Methotrexate—bone cancer	0.00048	0.00238	CcSEcCtD
Galantamine—Haemorrhage—Methotrexate—bone cancer	0.000477	0.00237	CcSEcCtD
Galantamine—Hepatitis—Methotrexate—bone cancer	0.000477	0.00237	CcSEcCtD
Galantamine—Pollakiuria—Doxorubicin—bone cancer	0.000477	0.00237	CcSEcCtD
Galantamine—Haematuria—Epirubicin—bone cancer	0.000475	0.00236	CcSEcCtD
Galantamine—Urinary tract disorder—Methotrexate—bone cancer	0.000472	0.00234	CcSEcCtD
Galantamine—Hepatobiliary disease—Epirubicin—bone cancer	0.000471	0.00234	CcSEcCtD
Galantamine—Epistaxis—Epirubicin—bone cancer	0.000469	0.00233	CcSEcCtD
Galantamine—Urethral disorder—Methotrexate—bone cancer	0.000468	0.00232	CcSEcCtD
Galantamine—Weight decreased—Doxorubicin—bone cancer	0.000467	0.00232	CcSEcCtD
Galantamine—Hyperglycaemia—Doxorubicin—bone cancer	0.000466	0.00231	CcSEcCtD
Galantamine—Pneumonia—Doxorubicin—bone cancer	0.000463	0.0023	CcSEcCtD
Galantamine—Visual impairment—Methotrexate—bone cancer	0.00046	0.00228	CcSEcCtD
Galantamine—Hypersensitivity—Cisplatin—bone cancer	0.000455	0.00226	CcSEcCtD
Galantamine—Bradycardia—Epirubicin—bone cancer	0.000455	0.00226	CcSEcCtD
Galantamine—Renal failure—Doxorubicin—bone cancer	0.000453	0.00225	CcSEcCtD
Galantamine—Neuropathy peripheral—Doxorubicin—bone cancer	0.000451	0.00224	CcSEcCtD
Galantamine—Haemoglobin—Epirubicin—bone cancer	0.000449	0.00223	CcSEcCtD
Galantamine—Rhinitis—Epirubicin—bone cancer	0.000448	0.00222	CcSEcCtD
Galantamine—Urinary tract infection—Doxorubicin—bone cancer	0.000448	0.00222	CcSEcCtD
Galantamine—Haemorrhage—Epirubicin—bone cancer	0.000447	0.00222	CcSEcCtD
Galantamine—Hepatitis—Epirubicin—bone cancer	0.000447	0.00222	CcSEcCtD
Galantamine—Eye disorder—Methotrexate—bone cancer	0.000446	0.00221	CcSEcCtD
Galantamine—Tinnitus—Methotrexate—bone cancer	0.000445	0.00221	CcSEcCtD
Galantamine—Asthenia—Cisplatin—bone cancer	0.000444	0.0022	CcSEcCtD
Galantamine—Cardiac disorder—Methotrexate—bone cancer	0.000443	0.0022	CcSEcCtD
Galantamine—Urinary tract disorder—Epirubicin—bone cancer	0.000441	0.00219	CcSEcCtD
Galantamine—Oedema peripheral—Epirubicin—bone cancer	0.00044	0.00218	CcSEcCtD
Galantamine—Haematuria—Doxorubicin—bone cancer	0.000439	0.00218	CcSEcCtD
Galantamine—Connective tissue disorder—Epirubicin—bone cancer	0.000439	0.00218	CcSEcCtD
Galantamine—Urethral disorder—Epirubicin—bone cancer	0.000438	0.00217	CcSEcCtD
Galantamine—Hepatobiliary disease—Doxorubicin—bone cancer	0.000436	0.00216	CcSEcCtD
Galantamine—Epistaxis—Doxorubicin—bone cancer	0.000434	0.00216	CcSEcCtD
Galantamine—Angiopathy—Methotrexate—bone cancer	0.000433	0.00215	CcSEcCtD
Galantamine—Immune system disorder—Methotrexate—bone cancer	0.000431	0.00214	CcSEcCtD
Galantamine—CHRNE—ErbB2/ErbB3 signaling events—JUN—bone cancer	0.000431	0.0179	CbGpPWpGaD
Galantamine—Visual impairment—Epirubicin—bone cancer	0.000431	0.00214	CcSEcCtD
Galantamine—Diarrhoea—Cisplatin—bone cancer	0.000423	0.0021	CcSEcCtD
Galantamine—Bradycardia—Doxorubicin—bone cancer	0.000421	0.00209	CcSEcCtD
Galantamine—Mental disorder—Methotrexate—bone cancer	0.000418	0.00208	CcSEcCtD
Galantamine—Eye disorder—Epirubicin—bone cancer	0.000418	0.00207	CcSEcCtD
Galantamine—Tinnitus—Epirubicin—bone cancer	0.000417	0.00207	CcSEcCtD
Galantamine—Malnutrition—Methotrexate—bone cancer	0.000416	0.00206	CcSEcCtD
Galantamine—Haemoglobin—Doxorubicin—bone cancer	0.000416	0.00206	CcSEcCtD
Galantamine—Flushing—Epirubicin—bone cancer	0.000415	0.00206	CcSEcCtD
Galantamine—Cardiac disorder—Epirubicin—bone cancer	0.000415	0.00206	CcSEcCtD
Galantamine—Rhinitis—Doxorubicin—bone cancer	0.000414	0.00206	CcSEcCtD
Galantamine—Hepatitis—Doxorubicin—bone cancer	0.000413	0.00205	CcSEcCtD
Galantamine—Haemorrhage—Doxorubicin—bone cancer	0.000413	0.00205	CcSEcCtD
Galantamine—Urinary tract disorder—Doxorubicin—bone cancer	0.000408	0.00203	CcSEcCtD
Galantamine—Oedema peripheral—Doxorubicin—bone cancer	0.000407	0.00202	CcSEcCtD
Galantamine—Dysgeusia—Methotrexate—bone cancer	0.000407	0.00202	CcSEcCtD
Galantamine—Connective tissue disorder—Doxorubicin—bone cancer	0.000406	0.00202	CcSEcCtD
Galantamine—Angiopathy—Epirubicin—bone cancer	0.000405	0.00201	CcSEcCtD
Galantamine—Urethral disorder—Doxorubicin—bone cancer	0.000405	0.00201	CcSEcCtD
Galantamine—Immune system disorder—Epirubicin—bone cancer	0.000404	0.002	CcSEcCtD
Galantamine—Back pain—Methotrexate—bone cancer	0.000402	0.002	CcSEcCtD
Galantamine—Arrhythmia—Epirubicin—bone cancer	0.000399	0.00198	CcSEcCtD
Galantamine—Visual impairment—Doxorubicin—bone cancer	0.000398	0.00198	CcSEcCtD
Galantamine—Vomiting—Cisplatin—bone cancer	0.000393	0.00195	CcSEcCtD
Galantamine—Vision blurred—Methotrexate—bone cancer	0.000392	0.00194	CcSEcCtD
Galantamine—Mental disorder—Epirubicin—bone cancer	0.000391	0.00194	CcSEcCtD
Galantamine—Rash—Cisplatin—bone cancer	0.00039	0.00193	CcSEcCtD
Galantamine—Dermatitis—Cisplatin—bone cancer	0.000389	0.00193	CcSEcCtD
Galantamine—Malnutrition—Epirubicin—bone cancer	0.000389	0.00193	CcSEcCtD
Galantamine—Eye disorder—Doxorubicin—bone cancer	0.000386	0.00192	CcSEcCtD
Galantamine—Ill-defined disorder—Methotrexate—bone cancer	0.000386	0.00191	CcSEcCtD
Galantamine—Tinnitus—Doxorubicin—bone cancer	0.000385	0.00191	CcSEcCtD
Galantamine—Anaemia—Methotrexate—bone cancer	0.000384	0.00191	CcSEcCtD
Galantamine—Flushing—Doxorubicin—bone cancer	0.000384	0.0019	CcSEcCtD
Galantamine—Cardiac disorder—Doxorubicin—bone cancer	0.000384	0.0019	CcSEcCtD
Galantamine—Flatulence—Epirubicin—bone cancer	0.000383	0.0019	CcSEcCtD
Galantamine—Tension—Epirubicin—bone cancer	0.000382	0.00189	CcSEcCtD
Galantamine—Dysgeusia—Epirubicin—bone cancer	0.000381	0.00189	CcSEcCtD
Galantamine—Nervousness—Epirubicin—bone cancer	0.000378	0.00188	CcSEcCtD
Galantamine—Back pain—Epirubicin—bone cancer	0.000376	0.00187	CcSEcCtD
Galantamine—Angiopathy—Doxorubicin—bone cancer	0.000375	0.00186	CcSEcCtD
Galantamine—Malaise—Methotrexate—bone cancer	0.000375	0.00186	CcSEcCtD
Galantamine—Muscle spasms—Epirubicin—bone cancer	0.000374	0.00186	CcSEcCtD
Galantamine—Immune system disorder—Doxorubicin—bone cancer	0.000373	0.00185	CcSEcCtD
Galantamine—Vertigo—Methotrexate—bone cancer	0.000373	0.00185	CcSEcCtD
Galantamine—Arrhythmia—Doxorubicin—bone cancer	0.000369	0.00183	CcSEcCtD
Galantamine—Nausea—Cisplatin—bone cancer	0.000367	0.00182	CcSEcCtD
Galantamine—Vision blurred—Epirubicin—bone cancer	0.000367	0.00182	CcSEcCtD
Galantamine—Cough—Methotrexate—bone cancer	0.000363	0.0018	CcSEcCtD
Galantamine—Mental disorder—Doxorubicin—bone cancer	0.000362	0.0018	CcSEcCtD
Galantamine—Ill-defined disorder—Epirubicin—bone cancer	0.000361	0.00179	CcSEcCtD
Galantamine—Convulsion—Methotrexate—bone cancer	0.00036	0.00179	CcSEcCtD
Galantamine—Malnutrition—Doxorubicin—bone cancer	0.00036	0.00179	CcSEcCtD
Galantamine—Anaemia—Epirubicin—bone cancer	0.00036	0.00178	CcSEcCtD
Galantamine—Agitation—Epirubicin—bone cancer	0.000357	0.00177	CcSEcCtD
Galantamine—Flatulence—Doxorubicin—bone cancer	0.000355	0.00176	CcSEcCtD
Galantamine—Myalgia—Methotrexate—bone cancer	0.000354	0.00176	CcSEcCtD
Galantamine—Arthralgia—Methotrexate—bone cancer	0.000354	0.00176	CcSEcCtD
Galantamine—Chest pain—Methotrexate—bone cancer	0.000354	0.00176	CcSEcCtD
Galantamine—Tension—Doxorubicin—bone cancer	0.000353	0.00175	CcSEcCtD
Galantamine—Dysgeusia—Doxorubicin—bone cancer	0.000352	0.00175	CcSEcCtD
Galantamine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.000351	0.00174	CcSEcCtD
Galantamine—Malaise—Epirubicin—bone cancer	0.000351	0.00174	CcSEcCtD
Galantamine—Discomfort—Methotrexate—bone cancer	0.00035	0.00174	CcSEcCtD
Galantamine—Nervousness—Doxorubicin—bone cancer	0.00035	0.00174	CcSEcCtD
Galantamine—Vertigo—Epirubicin—bone cancer	0.000349	0.00173	CcSEcCtD
Galantamine—Syncope—Epirubicin—bone cancer	0.000349	0.00173	CcSEcCtD
Galantamine—Back pain—Doxorubicin—bone cancer	0.000348	0.00173	CcSEcCtD
Galantamine—Muscle spasms—Doxorubicin—bone cancer	0.000346	0.00172	CcSEcCtD
Galantamine—Palpitations—Epirubicin—bone cancer	0.000344	0.00171	CcSEcCtD
Galantamine—Confusional state—Methotrexate—bone cancer	0.000342	0.0017	CcSEcCtD
Galantamine—Loss of consciousness—Epirubicin—bone cancer	0.000342	0.0017	CcSEcCtD
Galantamine—Cough—Epirubicin—bone cancer	0.000339	0.00168	CcSEcCtD
Galantamine—Vision blurred—Doxorubicin—bone cancer	0.000339	0.00168	CcSEcCtD
Galantamine—Convulsion—Epirubicin—bone cancer	0.000337	0.00167	CcSEcCtD
Galantamine—Hypertension—Epirubicin—bone cancer	0.000336	0.00167	CcSEcCtD
Galantamine—Ill-defined disorder—Doxorubicin—bone cancer	0.000334	0.00166	CcSEcCtD
Galantamine—Nervous system disorder—Methotrexate—bone cancer	0.000333	0.00165	CcSEcCtD
Galantamine—Anaemia—Doxorubicin—bone cancer	0.000333	0.00165	CcSEcCtD
Galantamine—Thrombocytopenia—Methotrexate—bone cancer	0.000332	0.00165	CcSEcCtD
Galantamine—Chest pain—Epirubicin—bone cancer	0.000331	0.00164	CcSEcCtD
Galantamine—Arthralgia—Epirubicin—bone cancer	0.000331	0.00164	CcSEcCtD
Galantamine—Myalgia—Epirubicin—bone cancer	0.000331	0.00164	CcSEcCtD
Galantamine—Agitation—Doxorubicin—bone cancer	0.000331	0.00164	CcSEcCtD
Galantamine—Anxiety—Epirubicin—bone cancer	0.00033	0.00164	CcSEcCtD
Galantamine—Skin disorder—Methotrexate—bone cancer	0.00033	0.00164	CcSEcCtD
Galantamine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.000329	0.00163	CcSEcCtD
Galantamine—Hyperhidrosis—Methotrexate—bone cancer	0.000328	0.00163	CcSEcCtD
Galantamine—Discomfort—Epirubicin—bone cancer	0.000327	0.00162	CcSEcCtD
Galantamine—Malaise—Doxorubicin—bone cancer	0.000325	0.00161	CcSEcCtD
Galantamine—Dry mouth—Epirubicin—bone cancer	0.000324	0.00161	CcSEcCtD
Galantamine—Vertigo—Doxorubicin—bone cancer	0.000323	0.00161	CcSEcCtD
Galantamine—Anorexia—Methotrexate—bone cancer	0.000323	0.0016	CcSEcCtD
Galantamine—Syncope—Doxorubicin—bone cancer	0.000323	0.0016	CcSEcCtD
Galantamine—Confusional state—Epirubicin—bone cancer	0.00032	0.00159	CcSEcCtD
Galantamine—Palpitations—Doxorubicin—bone cancer	0.000318	0.00158	CcSEcCtD
Galantamine—Hypotension—Methotrexate—bone cancer	0.000317	0.00157	CcSEcCtD
Galantamine—Loss of consciousness—Doxorubicin—bone cancer	0.000316	0.00157	CcSEcCtD
Galantamine—CYP3A4—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000315	0.0131	CbGpPWpGaD
Galantamine—Cough—Doxorubicin—bone cancer	0.000314	0.00156	CcSEcCtD
Galantamine—Shock—Epirubicin—bone cancer	0.000312	0.00155	CcSEcCtD
Galantamine—Convulsion—Doxorubicin—bone cancer	0.000312	0.00155	CcSEcCtD
Galantamine—Nervous system disorder—Epirubicin—bone cancer	0.000311	0.00155	CcSEcCtD
Galantamine—Thrombocytopenia—Epirubicin—bone cancer	0.000311	0.00154	CcSEcCtD
Galantamine—Hypertension—Doxorubicin—bone cancer	0.000311	0.00154	CcSEcCtD
Galantamine—Tachycardia—Epirubicin—bone cancer	0.00031	0.00154	CcSEcCtD
Galantamine—Musculoskeletal discomfort—Methotrexate—bone cancer	0.000309	0.00153	CcSEcCtD
Galantamine—Skin disorder—Epirubicin—bone cancer	0.000308	0.00153	CcSEcCtD
Galantamine—Hyperhidrosis—Epirubicin—bone cancer	0.000307	0.00152	CcSEcCtD
Galantamine—Insomnia—Methotrexate—bone cancer	0.000307	0.00152	CcSEcCtD
Galantamine—Chest pain—Doxorubicin—bone cancer	0.000306	0.00152	CcSEcCtD
Galantamine—Arthralgia—Doxorubicin—bone cancer	0.000306	0.00152	CcSEcCtD
Galantamine—Myalgia—Doxorubicin—bone cancer	0.000306	0.00152	CcSEcCtD
Galantamine—Anxiety—Doxorubicin—bone cancer	0.000305	0.00152	CcSEcCtD
Galantamine—Paraesthesia—Methotrexate—bone cancer	0.000305	0.00151	CcSEcCtD
Galantamine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.000304	0.00151	CcSEcCtD
Galantamine—Discomfort—Doxorubicin—bone cancer	0.000303	0.0015	CcSEcCtD
Galantamine—Anorexia—Epirubicin—bone cancer	0.000303	0.0015	CcSEcCtD
Galantamine—Somnolence—Methotrexate—bone cancer	0.000302	0.0015	CcSEcCtD
Galantamine—Dry mouth—Doxorubicin—bone cancer	0.0003	0.00149	CcSEcCtD
Galantamine—Dyspepsia—Methotrexate—bone cancer	0.000299	0.00148	CcSEcCtD
Galantamine—CHRNA9—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—bone cancer	0.000298	0.0124	CbGpPWpGaD
Galantamine—Hypotension—Epirubicin—bone cancer	0.000297	0.00147	CcSEcCtD
Galantamine—Confusional state—Doxorubicin—bone cancer	0.000296	0.00147	CcSEcCtD
Galantamine—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.000296	0.0123	CbGpPWpGaD
Galantamine—Decreased appetite—Methotrexate—bone cancer	0.000295	0.00146	CcSEcCtD
Galantamine—Gastrointestinal disorder—Methotrexate—bone cancer	0.000293	0.00145	CcSEcCtD
Galantamine—Fatigue—Methotrexate—bone cancer	0.000292	0.00145	CcSEcCtD
Galantamine—Musculoskeletal discomfort—Epirubicin—bone cancer	0.000289	0.00144	CcSEcCtD
Galantamine—Shock—Doxorubicin—bone cancer	0.000289	0.00143	CcSEcCtD
Galantamine—Nervous system disorder—Doxorubicin—bone cancer	0.000288	0.00143	CcSEcCtD
Galantamine—Thrombocytopenia—Doxorubicin—bone cancer	0.000288	0.00143	CcSEcCtD
Galantamine—Insomnia—Epirubicin—bone cancer	0.000287	0.00143	CcSEcCtD
Galantamine—Tachycardia—Doxorubicin—bone cancer	0.000287	0.00142	CcSEcCtD
Galantamine—Skin disorder—Doxorubicin—bone cancer	0.000285	0.00142	CcSEcCtD
Galantamine—Paraesthesia—Epirubicin—bone cancer	0.000285	0.00141	CcSEcCtD
Galantamine—Hyperhidrosis—Doxorubicin—bone cancer	0.000284	0.00141	CcSEcCtD
Galantamine—Somnolence—Epirubicin—bone cancer	0.000282	0.0014	CcSEcCtD
Galantamine—Anorexia—Doxorubicin—bone cancer	0.00028	0.00139	CcSEcCtD
Galantamine—Feeling abnormal—Methotrexate—bone cancer	0.00028	0.00139	CcSEcCtD
Galantamine—Dyspepsia—Epirubicin—bone cancer	0.000279	0.00139	CcSEcCtD
Galantamine—CYP2D6—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.000278	0.0116	CbGpPWpGaD
Galantamine—Gastrointestinal pain—Methotrexate—bone cancer	0.000277	0.00138	CcSEcCtD
Galantamine—Decreased appetite—Epirubicin—bone cancer	0.000276	0.00137	CcSEcCtD
Galantamine—Hypotension—Doxorubicin—bone cancer	0.000274	0.00136	CcSEcCtD
Galantamine—Gastrointestinal disorder—Epirubicin—bone cancer	0.000274	0.00136	CcSEcCtD
Galantamine—Fatigue—Epirubicin—bone cancer	0.000274	0.00136	CcSEcCtD
Galantamine—Constipation—Epirubicin—bone cancer	0.000271	0.00135	CcSEcCtD
Galantamine—Abdominal pain—Methotrexate—bone cancer	0.000268	0.00133	CcSEcCtD
Galantamine—Body temperature increased—Methotrexate—bone cancer	0.000268	0.00133	CcSEcCtD
Galantamine—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.000268	0.00133	CcSEcCtD
Galantamine—Insomnia—Doxorubicin—bone cancer	0.000266	0.00132	CcSEcCtD
Galantamine—Paraesthesia—Doxorubicin—bone cancer	0.000264	0.00131	CcSEcCtD
Galantamine—Feeling abnormal—Epirubicin—bone cancer	0.000262	0.0013	CcSEcCtD
Galantamine—Somnolence—Doxorubicin—bone cancer	0.000261	0.0013	CcSEcCtD
Galantamine—CHRNB3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—bone cancer	0.00026	0.0108	CbGpPWpGaD
Galantamine—Gastrointestinal pain—Epirubicin—bone cancer	0.00026	0.00129	CcSEcCtD
Galantamine—Dyspepsia—Doxorubicin—bone cancer	0.000259	0.00128	CcSEcCtD
Galantamine—Decreased appetite—Doxorubicin—bone cancer	0.000255	0.00127	CcSEcCtD
Galantamine—Gastrointestinal disorder—Doxorubicin—bone cancer	0.000254	0.00126	CcSEcCtD
Galantamine—Fatigue—Doxorubicin—bone cancer	0.000253	0.00126	CcSEcCtD
Galantamine—Constipation—Doxorubicin—bone cancer	0.000251	0.00125	CcSEcCtD
Galantamine—Body temperature increased—Epirubicin—bone cancer	0.000251	0.00125	CcSEcCtD
Galantamine—Abdominal pain—Epirubicin—bone cancer	0.000251	0.00125	CcSEcCtD
Galantamine—Hypersensitivity—Methotrexate—bone cancer	0.00025	0.00124	CcSEcCtD
Galantamine—CHRNA9—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—bone cancer	0.00025	0.0104	CbGpPWpGaD
Galantamine—CHRNB2—Circadian rythm related genes—GNA11—bone cancer	0.000248	0.0103	CbGpPWpGaD
Galantamine—CHRNB2—Circadian rythm related genes—EZH2—bone cancer	0.000247	0.0103	CbGpPWpGaD
Galantamine—CHRNA5—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—bone cancer	0.000247	0.0103	CbGpPWpGaD
Galantamine—Asthenia—Methotrexate—bone cancer	0.000243	0.00121	CcSEcCtD
Galantamine—Feeling abnormal—Doxorubicin—bone cancer	0.000242	0.0012	CcSEcCtD
Galantamine—Gastrointestinal pain—Doxorubicin—bone cancer	0.00024	0.00119	CcSEcCtD
Galantamine—CHRNG—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—bone cancer	0.000236	0.00981	CbGpPWpGaD
Galantamine—Hypersensitivity—Epirubicin—bone cancer	0.000234	0.00116	CcSEcCtD
Galantamine—Abdominal pain—Doxorubicin—bone cancer	0.000232	0.00115	CcSEcCtD
Galantamine—Body temperature increased—Doxorubicin—bone cancer	0.000232	0.00115	CcSEcCtD
Galantamine—CYP2D6—Xenobiotics—CYP3A4—bone cancer	0.000232	0.00967	CbGpPWpGaD
Galantamine—Diarrhoea—Methotrexate—bone cancer	0.000232	0.00115	CcSEcCtD
Galantamine—Asthenia—Epirubicin—bone cancer	0.000228	0.00113	CcSEcCtD
Galantamine—Dizziness—Methotrexate—bone cancer	0.000224	0.00111	CcSEcCtD
Galantamine—CHRNA9—Transmission across Chemical Synapses—BRAF—bone cancer	0.000224	0.00933	CbGpPWpGaD
Galantamine—CYP2D6—Tamoxifen metabolism—CYP3A4—bone cancer	0.000223	0.0093	CbGpPWpGaD
Galantamine—CHRNE—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—bone cancer	0.000221	0.00922	CbGpPWpGaD
Galantamine—CHRNB3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—bone cancer	0.000218	0.00909	CbGpPWpGaD
Galantamine—Diarrhoea—Epirubicin—bone cancer	0.000217	0.00108	CcSEcCtD
Galantamine—CHRNA1—ErbB2/ErbB3 signaling events—JUN—bone cancer	0.000217	0.00902	CbGpPWpGaD
Galantamine—Hypersensitivity—Doxorubicin—bone cancer	0.000216	0.00107	CcSEcCtD
Galantamine—Vomiting—Methotrexate—bone cancer	0.000216	0.00107	CcSEcCtD
Galantamine—Rash—Methotrexate—bone cancer	0.000214	0.00106	CcSEcCtD
Galantamine—Dermatitis—Methotrexate—bone cancer	0.000214	0.00106	CcSEcCtD
Galantamine—Headache—Methotrexate—bone cancer	0.000213	0.00105	CcSEcCtD
Galantamine—Asthenia—Doxorubicin—bone cancer	0.000211	0.00105	CcSEcCtD
Galantamine—Dizziness—Epirubicin—bone cancer	0.00021	0.00104	CcSEcCtD
Galantamine—CYP2D6—Metapathway biotransformation—CYP4V2—bone cancer	0.000207	0.00862	CbGpPWpGaD
Galantamine—CHRNA5—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—bone cancer	0.000207	0.00861	CbGpPWpGaD
Galantamine—Vomiting—Epirubicin—bone cancer	0.000202	0.001	CcSEcCtD
Galantamine—Nausea—Methotrexate—bone cancer	0.000201	0.001	CcSEcCtD
Galantamine—Diarrhoea—Doxorubicin—bone cancer	0.000201	0.000998	CcSEcCtD
Galantamine—Rash—Epirubicin—bone cancer	0.0002	0.000994	CcSEcCtD
Galantamine—Dermatitis—Epirubicin—bone cancer	0.0002	0.000993	CcSEcCtD
Galantamine—Headache—Epirubicin—bone cancer	0.000199	0.000987	CcSEcCtD
Galantamine—CHRNG—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—bone cancer	0.000197	0.00822	CbGpPWpGaD
Galantamine—CHRNB3—Transmission across Chemical Synapses—BRAF—bone cancer	0.000196	0.00815	CbGpPWpGaD
Galantamine—Dizziness—Doxorubicin—bone cancer	0.000194	0.000964	CcSEcCtD
Galantamine—Nausea—Epirubicin—bone cancer	0.000189	0.000936	CcSEcCtD
Galantamine—CHRNA9—Transmission across Chemical Synapses—MDM2—bone cancer	0.000188	0.00781	CbGpPWpGaD
Galantamine—CHRNA6—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—bone cancer	0.000187	0.00779	CbGpPWpGaD
Galantamine—Vomiting—Doxorubicin—bone cancer	0.000187	0.000927	CcSEcCtD
Galantamine—CHRNA5—Transmission across Chemical Synapses—BRAF—bone cancer	0.000186	0.00773	CbGpPWpGaD
Galantamine—CHRNE—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—bone cancer	0.000186	0.00773	CbGpPWpGaD
Galantamine—Rash—Doxorubicin—bone cancer	0.000185	0.000919	CcSEcCtD
Galantamine—Dermatitis—Doxorubicin—bone cancer	0.000185	0.000918	CcSEcCtD
Galantamine—Headache—Doxorubicin—bone cancer	0.000184	0.000913	CcSEcCtD
Galantamine—CHRNG—Transmission across Chemical Synapses—BRAF—bone cancer	0.000177	0.00737	CbGpPWpGaD
Galantamine—Nausea—Doxorubicin—bone cancer	0.000174	0.000866	CcSEcCtD
Galantamine—CHRNA9—Neuronal System—BRAF—bone cancer	0.000172	0.00715	CbGpPWpGaD
Galantamine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.00017	0.00708	CbGpPWpGaD
Galantamine—CHRNE—Transmission across Chemical Synapses—BRAF—bone cancer	0.000166	0.00693	CbGpPWpGaD
Galantamine—CHRNB2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—bone cancer	0.000165	0.00686	CbGpPWpGaD
Galantamine—CHRNB3—Transmission across Chemical Synapses—MDM2—bone cancer	0.000164	0.00683	CbGpPWpGaD
Galantamine—CHRNA6—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—bone cancer	0.000157	0.00653	CbGpPWpGaD
Galantamine—ACHE—ATF-2 transcription factor network—PLAU—bone cancer	0.000156	0.00651	CbGpPWpGaD
Galantamine—CHRNA5—Transmission across Chemical Synapses—MDM2—bone cancer	0.000156	0.00648	CbGpPWpGaD
Galantamine—CHRNB3—Neuronal System—BRAF—bone cancer	0.00015	0.00625	CbGpPWpGaD
Galantamine—CHRNG—Transmission across Chemical Synapses—MDM2—bone cancer	0.000148	0.00618	CbGpPWpGaD
Galantamine—ACHE—ATF-2 transcription factor network—CDK4—bone cancer	0.000148	0.00615	CbGpPWpGaD
Galantamine—CHRNA9—Neuronal System—MDM2—bone cancer	0.000144	0.00599	CbGpPWpGaD
Galantamine—CHRNA5—Neuronal System—BRAF—bone cancer	0.000142	0.00592	CbGpPWpGaD
Galantamine—CHRNA6—Transmission across Chemical Synapses—BRAF—bone cancer	0.000141	0.00586	CbGpPWpGaD
Galantamine—CHRNE—Transmission across Chemical Synapses—MDM2—bone cancer	0.000139	0.00581	CbGpPWpGaD
Galantamine—CHRNB2—Circadian rythm related genes—CDK4—bone cancer	0.000139	0.0058	CbGpPWpGaD
Galantamine—CHRNB2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—bone cancer	0.000138	0.00575	CbGpPWpGaD
Galantamine—CHRNG—Neuronal System—BRAF—bone cancer	0.000136	0.00565	CbGpPWpGaD
Galantamine—CYP3A4—Metapathway biotransformation—CYP4V2—bone cancer	0.000135	0.00564	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	0.000132	0.0055	CbGpPWpGaD
Galantamine—CHRND—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—bone cancer	0.000131	0.00546	CbGpPWpGaD
Galantamine—CHRNB4—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—bone cancer	0.00013	0.0054	CbGpPWpGaD
Galantamine—ACHE—Metabolism of proteins—MOGS—bone cancer	0.000129	0.00536	CbGpPWpGaD
Galantamine—ACHE—ATF-2 transcription factor network—RB1—bone cancer	0.000128	0.00535	CbGpPWpGaD
Galantamine—CHRNE—Neuronal System—BRAF—bone cancer	0.000128	0.00531	CbGpPWpGaD
Galantamine—CHRNB3—Neuronal System—MDM2—bone cancer	0.000126	0.00523	CbGpPWpGaD
Galantamine—CHRNB2—Transmission across Chemical Synapses—BRAF—bone cancer	0.000124	0.00516	CbGpPWpGaD
Galantamine—ACHE—ATF-2 transcription factor network—MMP2—bone cancer	0.000123	0.00513	CbGpPWpGaD
Galantamine—CHRNA5—Neuronal System—MDM2—bone cancer	0.000119	0.00496	CbGpPWpGaD
Galantamine—CHRNA3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—bone cancer	0.000119	0.00494	CbGpPWpGaD
Galantamine—CHRNA6—Transmission across Chemical Synapses—MDM2—bone cancer	0.000118	0.00491	CbGpPWpGaD
Galantamine—BCHE—Metabolism of proteins—MOGS—bone cancer	0.000115	0.00478	CbGpPWpGaD
Galantamine—CHRNG—Neuronal System—MDM2—bone cancer	0.000114	0.00473	CbGpPWpGaD
Galantamine—CHRNA7—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—bone cancer	0.000113	0.00469	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	0.000112	0.00467	CbGpPWpGaD
Galantamine—CHRNA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—bone cancer	0.000111	0.00464	CbGpPWpGaD
Galantamine—CHRNB2—SIDS Susceptibility Pathways—JUN—bone cancer	0.00011	0.00458	CbGpPWpGaD
Galantamine—CHRND—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—bone cancer	0.00011	0.00457	CbGpPWpGaD
Galantamine—CHRNB4—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—bone cancer	0.000109	0.00452	CbGpPWpGaD
Galantamine—CHRNA6—Neuronal System—BRAF—bone cancer	0.000108	0.00449	CbGpPWpGaD
Galantamine—CHRNE—Neuronal System—MDM2—bone cancer	0.000107	0.00445	CbGpPWpGaD
Galantamine—CHRNA2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—bone cancer	0.000106	0.00441	CbGpPWpGaD
Galantamine—CHRNB2—Transmission across Chemical Synapses—MDM2—bone cancer	0.000104	0.00432	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	0.000102	0.00426	CbGpPWpGaD
Galantamine—CHRNA3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—bone cancer	9.94e-05	0.00414	CbGpPWpGaD
Galantamine—CHRND—Transmission across Chemical Synapses—BRAF—bone cancer	9.85e-05	0.0041	CbGpPWpGaD
Galantamine—CHRNB4—Transmission across Chemical Synapses—BRAF—bone cancer	9.75e-05	0.00406	CbGpPWpGaD
Galantamine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	9.64e-05	0.00401	CbGpPWpGaD
Galantamine—ACHE—ATF-2 transcription factor network—JUN—bone cancer	9.52e-05	0.00396	CbGpPWpGaD
Galantamine—CYP2D6—Oxidation by Cytochrome P450—CYP3A4—bone cancer	9.51e-05	0.00396	CbGpPWpGaD
Galantamine—CHRNB2—Neuronal System—BRAF—bone cancer	9.49e-05	0.00395	CbGpPWpGaD
Galantamine—CHRNA7—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—bone cancer	9.43e-05	0.00393	CbGpPWpGaD
Galantamine—CHRNA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—bone cancer	9.33e-05	0.00389	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	9.31e-05	0.00388	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	9.18e-05	0.00382	CbGpPWpGaD
Galantamine—CHRNA4—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—bone cancer	9.18e-05	0.00382	CbGpPWpGaD
Galantamine—CHRNA6—Neuronal System—MDM2—bone cancer	9.03e-05	0.00376	CbGpPWpGaD
Galantamine—CHRNB2—Circadian rythm related genes—JUN—bone cancer	8.98e-05	0.00374	CbGpPWpGaD
Galantamine—CHRNA3—Transmission across Chemical Synapses—BRAF—bone cancer	8.92e-05	0.00371	CbGpPWpGaD
Galantamine—CHRNA2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—bone cancer	8.87e-05	0.00369	CbGpPWpGaD
Galantamine—CHRNB4—SIDS Susceptibility Pathways—JUN—bone cancer	8.66e-05	0.00361	CbGpPWpGaD
Galantamine—CHRNA7—Transmission across Chemical Synapses—BRAF—bone cancer	8.46e-05	0.00352	CbGpPWpGaD
Galantamine—CHRNA1—Transmission across Chemical Synapses—BRAF—bone cancer	8.37e-05	0.00349	CbGpPWpGaD
Galantamine—CHRND—Transmission across Chemical Synapses—MDM2—bone cancer	8.25e-05	0.00344	CbGpPWpGaD
Galantamine—CHRNB4—Transmission across Chemical Synapses—MDM2—bone cancer	8.17e-05	0.0034	CbGpPWpGaD
Galantamine—CHRNA2—Transmission across Chemical Synapses—BRAF—bone cancer	7.96e-05	0.00331	CbGpPWpGaD
Galantamine—CHRNB2—Neuronal System—MDM2—bone cancer	7.95e-05	0.00331	CbGpPWpGaD
Galantamine—CYP2D6—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	7.82e-05	0.00325	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	7.78e-05	0.00324	CbGpPWpGaD
Galantamine—CHRNA4—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—bone cancer	7.69e-05	0.0032	CbGpPWpGaD
Galantamine—CHRND—Neuronal System—BRAF—bone cancer	7.55e-05	0.00314	CbGpPWpGaD
Galantamine—CHRNA7—SIDS Susceptibility Pathways—JUN—bone cancer	7.52e-05	0.00313	CbGpPWpGaD
Galantamine—CHRNA3—Transmission across Chemical Synapses—MDM2—bone cancer	7.47e-05	0.00311	CbGpPWpGaD
Galantamine—CHRNB4—Neuronal System—BRAF—bone cancer	7.47e-05	0.00311	CbGpPWpGaD
Galantamine—CHRNA7—Transmission across Chemical Synapses—MDM2—bone cancer	7.09e-05	0.00295	CbGpPWpGaD
Galantamine—ACHE—Metabolism of proteins—TUBB4B—bone cancer	7.05e-05	0.00294	CbGpPWpGaD
Galantamine—CHRNA1—Transmission across Chemical Synapses—MDM2—bone cancer	7.02e-05	0.00292	CbGpPWpGaD
Galantamine—CHRNA4—Transmission across Chemical Synapses—BRAF—bone cancer	6.9e-05	0.00287	CbGpPWpGaD
Galantamine—CHRNA3—Neuronal System—BRAF—bone cancer	6.83e-05	0.00284	CbGpPWpGaD
Galantamine—CHRNA2—Transmission across Chemical Synapses—MDM2—bone cancer	6.67e-05	0.00278	CbGpPWpGaD
Galantamine—CHRNA7—Neuronal System—BRAF—bone cancer	6.48e-05	0.0027	CbGpPWpGaD
Galantamine—CHRNA1—Neuronal System—BRAF—bone cancer	6.42e-05	0.00267	CbGpPWpGaD
Galantamine—CHRND—Neuronal System—MDM2—bone cancer	6.32e-05	0.00263	CbGpPWpGaD
Galantamine—BCHE—Metabolism of proteins—TUBB4B—bone cancer	6.29e-05	0.00262	CbGpPWpGaD
Galantamine—CHRNB4—Neuronal System—MDM2—bone cancer	6.26e-05	0.00261	CbGpPWpGaD
Galantamine—CHRNA4—SIDS Susceptibility Pathways—JUN—bone cancer	6.13e-05	0.00255	CbGpPWpGaD
Galantamine—CHRNA2—Neuronal System—BRAF—bone cancer	6.1e-05	0.00254	CbGpPWpGaD
Galantamine—ACHE—Metabolism of proteins—TUBB2A—bone cancer	6.09e-05	0.00253	CbGpPWpGaD
Galantamine—ACHE—Metabolism—NDUFA12—bone cancer	6.07e-05	0.00253	CbGpPWpGaD
Galantamine—CHRNB2—Circadian rythm related genes—TP53—bone cancer	5.93e-05	0.00247	CbGpPWpGaD
Galantamine—CHRNA4—Transmission across Chemical Synapses—MDM2—bone cancer	5.78e-05	0.00241	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	5.77e-05	0.0024	CbGpPWpGaD
Galantamine—CHRNA3—Neuronal System—MDM2—bone cancer	5.72e-05	0.00238	CbGpPWpGaD
Galantamine—CHRNA7—Neuronal System—MDM2—bone cancer	5.43e-05	0.00226	CbGpPWpGaD
Galantamine—BCHE—Metabolism of proteins—TUBB2A—bone cancer	5.43e-05	0.00226	CbGpPWpGaD
Galantamine—BCHE—Metabolism—NDUFA12—bone cancer	5.41e-05	0.00225	CbGpPWpGaD
Galantamine—CHRNA1—Neuronal System—MDM2—bone cancer	5.38e-05	0.00224	CbGpPWpGaD
Galantamine—CHRNA4—Neuronal System—BRAF—bone cancer	5.29e-05	0.0022	CbGpPWpGaD
Galantamine—CHRNA2—Neuronal System—MDM2—bone cancer	5.11e-05	0.00213	CbGpPWpGaD
Galantamine—ACHE—Metabolism—NT5C3A—bone cancer	5.03e-05	0.00209	CbGpPWpGaD
Galantamine—ACHE—Transmission across Chemical Synapses—BRAF—bone cancer	4.92e-05	0.00205	CbGpPWpGaD
Galantamine—BCHE—Metabolism—NT5C3A—bone cancer	4.48e-05	0.00187	CbGpPWpGaD
Galantamine—CHRNA4—Neuronal System—MDM2—bone cancer	4.43e-05	0.00184	CbGpPWpGaD
Galantamine—BCHE—Transmission across Chemical Synapses—BRAF—bone cancer	4.39e-05	0.00183	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	4.28e-05	0.00178	CbGpPWpGaD
Galantamine—ACHE—Metabolism of proteins—EIF2S1—bone cancer	4.25e-05	0.00177	CbGpPWpGaD
Galantamine—CYP2D6—Biological oxidations—CYP3A4—bone cancer	4.15e-05	0.00173	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	4.12e-05	0.00172	CbGpPWpGaD
Galantamine—ACHE—Transmission across Chemical Synapses—MDM2—bone cancer	4.12e-05	0.00172	CbGpPWpGaD
Galantamine—CYP2D6—Metapathway biotransformation—CYP3A4—bone cancer	4.09e-05	0.0017	CbGpPWpGaD
Galantamine—BCHE—Metabolism of proteins—EIF2S1—bone cancer	3.79e-05	0.00158	CbGpPWpGaD
Galantamine—ACHE—Neuronal System—BRAF—bone cancer	3.77e-05	0.00157	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	3.72e-05	0.00155	CbGpPWpGaD
Galantamine—BCHE—Transmission across Chemical Synapses—MDM2—bone cancer	3.68e-05	0.00153	CbGpPWpGaD
Galantamine—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	3.58e-05	0.00149	CbGpPWpGaD
Galantamine—CYP2D6—Biological oxidations—GSTP1—bone cancer	3.55e-05	0.00148	CbGpPWpGaD
Galantamine—CYP2D6—Metapathway biotransformation—GSTP1—bone cancer	3.5e-05	0.00146	CbGpPWpGaD
Galantamine—BCHE—Neuronal System—BRAF—bone cancer	3.36e-05	0.0014	CbGpPWpGaD
Galantamine—ACHE—Neuronal System—MDM2—bone cancer	3.16e-05	0.00132	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	2.92e-05	0.00122	CbGpPWpGaD
Galantamine—BCHE—Neuronal System—MDM2—bone cancer	2.82e-05	0.00117	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—NDUFA12—bone cancer	2.49e-05	0.00104	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	2.45e-05	0.00102	CbGpPWpGaD
Galantamine—CYP3A4—Biological oxidations—GSTP1—bone cancer	2.32e-05	0.000967	CbGpPWpGaD
Galantamine—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	2.29e-05	0.000953	CbGpPWpGaD
Galantamine—ACHE—Metabolism—ENO2—bone cancer	2.2e-05	0.000917	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—NT5C3A—bone cancer	2.06e-05	0.000859	CbGpPWpGaD
Galantamine—ACHE—Metabolism—DHFR—bone cancer	2.04e-05	0.000851	CbGpPWpGaD
Galantamine—BCHE—Metabolism—ENO2—bone cancer	1.96e-05	0.000818	CbGpPWpGaD
Galantamine—ACHE—Metabolism—GNA11—bone cancer	1.91e-05	0.000795	CbGpPWpGaD
Galantamine—BCHE—Metabolism—DHFR—bone cancer	1.82e-05	0.000759	CbGpPWpGaD
Galantamine—ACHE—Metabolism of proteins—MMP2—bone cancer	1.74e-05	0.000723	CbGpPWpGaD
Galantamine—ACHE—Metabolism—CYP3A4—bone cancer	1.73e-05	0.000721	CbGpPWpGaD
Galantamine—ACHE—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.72e-05	0.000717	CbGpPWpGaD
Galantamine—BCHE—Metabolism—GNA11—bone cancer	1.7e-05	0.000709	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—NDUFA12—bone cancer	1.63e-05	0.000677	CbGpPWpGaD
Galantamine—BCHE—Metabolism of proteins—MMP2—bone cancer	1.55e-05	0.000645	CbGpPWpGaD
Galantamine—BCHE—Metabolism—CYP3A4—bone cancer	1.54e-05	0.000643	CbGpPWpGaD
Galantamine—BCHE—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.54e-05	0.00064	CbGpPWpGaD
Galantamine—ACHE—Metabolism—GSTP1—bone cancer	1.48e-05	0.000616	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—NT5C3A—bone cancer	1.35e-05	0.000561	CbGpPWpGaD
Galantamine—BCHE—Metabolism—GSTP1—bone cancer	1.32e-05	0.00055	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—ENO2—bone cancer	9.03e-06	0.000376	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—DHFR—bone cancer	8.38e-06	0.000349	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—GNA11—bone cancer	7.83e-06	0.000326	CbGpPWpGaD
Galantamine—ACHE—Metabolism—PTGS2—bone cancer	7.67e-06	0.000319	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—CYP3A4—bone cancer	7.1e-06	0.000296	CbGpPWpGaD
Galantamine—BCHE—Metabolism—PTGS2—bone cancer	6.84e-06	0.000285	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—GSTP1—bone cancer	6.07e-06	0.000253	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—ENO2—bone cancer	5.91e-06	0.000246	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—DHFR—bone cancer	5.48e-06	0.000228	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—GNA11—bone cancer	5.12e-06	0.000213	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—GSTP1—bone cancer	3.97e-06	0.000165	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—PTGS2—bone cancer	3.15e-06	0.000131	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—PTGS2—bone cancer	2.06e-06	8.56e-05	CbGpPWpGaD
